The Pathogen Is Only the Beginning: 10 Things My Research Into Lyme and Bartonella Is Changing About How I Understand Chronic Illness

The deeper I go into Lyme disease and Bartonella, the more convinced I become that identifying the organism is only the first layer of the problem. When people hear “Lyme” or “Bartonella,” the conversation often immediately becomes about killing the bacteria. That matters when an active infection is actually present, but it does not explain the entire illness. It does not explain why one person develops neurological symptoms, another develops severe fatigue, another develops vascular or autonomic problems, another becomes highly reactive to foods and chemicals, and another person exposed to a similar organism recovers without developing a chronic multisystem illness.

The missing part of the conversation is often the host. What is the organism doing inside the body? What nutrients does it need? Which immune pathways recognize it, and which ones does it evade? What happens to mitochondria while the immune system is fighting it? What happens to glutamate, tryptophan, calcium, oxidative stress, endothelial function, and cellular energy production? And perhaps most importantly, what was different about the person before the infection ever occurred that made one biological system more vulnerable than another?

That is the direction my research has been moving. These are ten things that have changed how I now think about Lyme disease and Bartonella.

1. Lyme and Bartonella may appear in the same clinical conversation, but they are metabolically very different organisms. Borrelia burgdorferi has an unusually stripped-down metabolism. It does not operate a complete TCA cycle and oxidative phosphorylation system like our mitochondria. It depends heavily on glycolysis and nutrients obtained from its environment. Bartonella is different. It retains a TCA cycle and respiratory machinery and can use host-derived metabolic substrates, including amino acids and organic acids, to generate energy.

One pathway I find particularly interesting in Bartonella is glutamine and glutamate metabolism. Glutamate can feed into alpha-ketoglutarate, which then enters the TCA cycle and contributes to production of metabolites such as succinate and reducing equivalents such as NADH that ultimately support bacterial ATP production.

What does that mean in plain language? It means two infections that produce similar symptoms may be placing completely different metabolic demands on the body. We should therefore stop speaking about “what tick-borne disease depletes” as if every organism uses the same resources. The better question is which organism is present, where it is living, what it is using for fuel, and whether that demand is large enough to disturb the host’s own metabolism.

For Bartonella, I am increasingly interested in whether infection can meaningfully influence the host glutamine-glutamate-alpha-ketoglutarate-succinate axis. That is important because these are not simply nutrients. They are deeply involved in mitochondrial metabolism, immune signaling, redox biology, and neurological function.

2. A person can be extremely inflamed and still have an immune response that is ineffective at clearing the organism. This is one of the most important ideas to understand. Inflammation and antimicrobial immunity are not the same thing.

A patient may have high cytokine activity, pain, neurological symptoms, oxidative stress, vascular irritation, or mast-cell activation and still not be mounting the particular immune response needed to eliminate the infection efficiently. Successful pathogens survive because they have evolved ways to interfere with immune recognition and clearance.

Borrelia can change some of the antigens presented to the immune system and can interfere with complement-mediated killing. Bartonella uses other strategies. It can occupy endothelial cells and erythrocytes, where it becomes much less exposed to circulating immune mechanisms. It can also inject proteins into host cells that alter cellular signaling. Its unusual lipid A produces very weak conventional TLR4 activation compared with the LPS of many other Gram-negative bacteria, while other Bartonella components can engage pathways such as TLR2.

This means the body may still know that something is wrong and continue producing inflammation, yet that inflammation may not translate into effective eradication. In some cases, the immune response may begin causing more collateral injury to the host than damage to the pathogen.

That changes the clinical question. Instead of simply asking whether the immune system is “weak” or “strong,” I want to know which part of immunity is activated, which part is being avoided or suppressed, and whether the inflammatory response is actually helping clear the organism.

3. Some of what we call mitochondrial dysfunction may begin as deliberate immune metabolic reprogramming. Immune cells do not use metabolism the same way when they are activated. During infection and inflammation, signaling through pathways such as PI3K, AKT, mTOR, and HIF can push immune cells toward greater glycolysis.

In simple terms, the cell begins using more glucose and producing more lactate because glycolysis can rapidly support inflammatory activity. Initially, this does not necessarily mean the mitochondria are damaged. It may be an intentional metabolic program designed to support an immune response.

The problem is what happens when that metabolic state does not switch off.

If inflammatory signaling remains active for a long period, the cell may continue relying heavily on glycolysis while mitochondrial substrate use, redox balance, nutrient demand, and oxidative stress begin changing. A response that was initially adaptive can eventually become metabolically expensive.

This distinction matters because someone with high lactate, exercise intolerance, or reduced energy may not simply have “broken mitochondria.” The first question may be why the immune system pushed metabolism into that state and whether the mitochondria are now damaged, merely reprogrammed, or both.

That is a very different way of thinking about fatigue.

4. Bartonella does not simply hide inside host cells. It can actively change how those cells behave. Bartonella has a molecular system called VirB/VirD4 that allows it to deliver bacterial effector proteins directly into host cells. I think of this less as passive infection and more as cellular reprogramming.

Those bacterial proteins can influence the host cytoskeleton, cell survival, inflammatory signaling, and pathways involved in vascular growth. Some Bartonella effectors can interfere with apoptosis, the normal process through which damaged or infected cells are instructed to die. From the bacterium’s perspective, keeping an infected endothelial cell alive creates a more stable environment in which to survive.

Other pathways influenced during Bartonella infection involve cAMP, STAT3, Rho-family proteins, HIF-1 alpha, VEGF, and related signaling systems.

This is important because an intracellular infection is not simply a bacterium sitting quietly inside a cell. The bacterium may be changing the biological decisions of that cell.

This is also why there are interesting parallels with pathways studied in cancer. Cancer cells frequently manipulate apoptosis, angiogenesis, metabolism, and immune signaling. Bartonella can intersect with some of those same pathways. That does not mean Bartonella causes cancer. It means very different biological systems can exploit the same cellular machinery because those pathways control survival, nutrients, growth, and vascular support.

5. Oxidative stress may be where the immune system’s attempt to kill the pathogen begins damaging the host as well. Reactive oxygen species are not simply harmful chemicals. The immune system deliberately generates them because they can damage microorganisms.

The difficulty is that pathogens also evolve antioxidant defenses.

Borrelia is particularly interesting because of its unusual manganese biology and its reliance on manganese-dependent antioxidant mechanisms. That means the immune system may increase oxidative pressure in an attempt to control Borrelia while the organism has specific systems that help it tolerate that pressure.

The host’s mitochondria, membranes, proteins, and antioxidant systems are exposed to the same environment.

Over time, this can create a biological mismatch. The body continues producing oxidative stress because it is trying to control the infection, but the pathogen is not completely eliminated. Meanwhile the host accumulates oxidative damage.

This is why simply saying “oxidative stress is high” is not enough. I want to know where that oxidative stress is coming from. Is it NADPH oxidase? Mitochondria? Nitric oxide chemistry? Activated immune cells? Several pathways at once? What is happening to glutathione, NADPH, and mitochondrial redox balance?

And importantly, is the oxidative response actually helping eliminate the organism?

That distinction matters before assuming that simply adding more antioxidants solves the problem.

6. Mineral abnormalities matter, but they do not automatically mean the pathogen has consumed all of the body’s minerals. Different organisms have very different metal requirements. Borrelia has unusual manganese requirements. Bartonella depends heavily on host-derived heme because it cannot fully synthesize the heme needed for its own respiratory metabolism.

But if a patient has low serum iron, that does not automatically mean Bartonella has “used up the iron.”

Inflammation itself dramatically changes mineral distribution. In the case of iron, inflammatory signaling can increase hepcidin. Hepcidin reduces ferroportin activity, causing iron to become trapped inside cells and storage compartments. Serum iron falls even though the problem may be redistribution rather than simple whole-body depletion.

This is part of nutritional immunity. The body deliberately attempts to hide certain nutrients from pathogens.

Similar principles can affect zinc, copper, manganese, magnesium, and other minerals through changes in transport, intestinal absorption, kidney handling, binding proteins, and intracellular sequestration.

So when I see an abnormal nutrient result, I now separate three possibilities. The person may truly be deficient. The nutrient may be present but redistributed because of inflammation. Or the pathogen may have a specific nutrient dependency that changes local availability.

Those three situations can look similar on a laboratory report but mean very different things biologically.

7. The tryptophan-kynurenine pathway may be one of the most important bridges between infection and neurological symptoms. This pathway has become a major focus of my research because it connects immune activation, the gut, neurotransmitter biology, and brain metabolism.

During inflammation, interferon signaling can activate an enzyme called IDO1. IDO1 redirects tryptophan toward the kynurenine pathway. Kynurenine can then be converted into several metabolites, including kynurenic acid, 3-hydroxykynurenine, and quinolinic acid.

Quinolinic acid is particularly interesting because it can activate NMDA receptors. NMDA receptors are major glutamate receptors involved in excitatory signaling in the brain.

Now look at what normally happens to glutamate. Neurons release glutamate to communicate. Astrocytes surrounding those neurons rapidly remove excess glutamate through EAAT transporters. Inside the astrocyte, glutamate is converted into glutamine by glutamine synthetase. That reaction requires ATP. The glutamine can then be returned to neurons and reused.

This system helps prevent glutamate from accumulating outside neurons.

Now imagine inflammation disrupting both sides of this system. Interferon increases IDO1 activity and produces more quinolinic acid, increasing NMDA stimulation. At the same time, oxidative stress or mitochondrial dysfunction impairs astrocytic ATP production or glutamate transport, so extracellular glutamate is cleared less efficiently.

Now NMDA receptors may be receiving stronger stimulation from two directions: more quinolinic acid and more persistent glutamate.

That matters because NMDA receptors allow calcium to enter neurons.

So a pathway that begins with immune activation can potentially become a neurological pathway: inflammation leads to IDO1 activation, tryptophan is shunted toward kynurenine and quinolinic acid, glutamate clearance becomes less efficient, NMDA activity increases, calcium influx rises, and mitochondrial stress may follow.

That is much more informative than simply saying someone has “neuroinflammation.”

8. Calcium may not be the original problem. The problem may be what happens when calcium reaches mitochondria that no longer have enough reserve to handle the signal. Calcium is essential for normal cellular function. Neurons use it, muscles use it, mast cells use it, and mitochondria use it.

When a cell becomes active, calcium can enter the mitochondrial matrix and stimulate metabolic enzymes. This increases TCA-cycle activity and produces more NADH. NADH donates electrons to Complex I of the electron transport chain, allowing mitochondria to increase ATP production.

Under healthy conditions, this is beneficial. Calcium tells the mitochondria that the cell is working harder and needs more energy.

The problem develops when the demand and the capacity no longer match.

Imagine calcium continuing to stimulate the TCA cycle and NADH production while the electron transport chain has become damaged, highly reduced, poorly oxygenated, or otherwise unable to oxidize NADH efficiently. NADH production can begin exceeding NADH oxidation.

The NADH-to-NAD ratio rises. Electron carriers remain excessively reduced. Electrons become more likely to leak from the respiratory chain and react with oxygen, producing superoxide.

Now add inflammatory nitric oxide. Superoxide can react with nitric oxide to form peroxynitrite.

Peroxynitrite can damage mitochondrial proteins, lipids, and vulnerable iron-sulfur enzymes. That can further reduce mitochondrial respiratory capacity. The mitochondrion then becomes even less capable of oxidizing NADH, increasing redox pressure and potentially producing still more oxidative stress.

That is how a feedback loop can develop.

This is why simply measuring serum calcium tells us almost nothing about this mechanism. What matters is intracellular calcium compartmentation. Calcium inside the cytoplasm, endoplasmic reticulum, and mitochondrial matrix are very different things.

The real question is whether the mitochondria have enough respiratory reserve to process the metabolic signal they are receiving.

9. Bartonella has made me look much more closely at the endothelium, because the endothelium may connect an infection to many different organ systems. The endothelium is often described as the lining of blood vessels, but that description does not capture what it actually does.

Endothelial cells regulate vascular tone, nitric oxide, permeability, coagulation, immune-cell trafficking, microvascular blood flow, angiogenesis, and tissue oxygen delivery.

Bartonella has a strong relationship with endothelial cells and can alter endothelial survival pathways, cytoskeletal organization, HIF-1 alpha signaling, VEGF production, and vascular growth signaling.

Once the endothelium becomes involved, it becomes easier to understand how one infection could potentially influence multiple systems.

If vascular permeability changes, fluid distribution can change. If nitric oxide signaling changes, blood-vessel tone can change. If immune-cell adhesion molecules increase, leukocyte trafficking can change. If microvascular perfusion deteriorates, oxygen delivery to tissues can change. If VEGF becomes chronically elevated, vascular permeability and angiogenic signaling can change.

That creates a plausible bridge between infection and some vascular, neurological, exercise-related, and autonomic symptoms.

But this is also where scientific discipline is essential. Bartonella affecting endothelial biology does not prove that every patient with POTS, mast-cell activation, small-fiber neuropathy, or chronic fatigue has Bartonella.

The pathway needs to be demonstrated in the person, not assumed because the symptoms fit.

10. The most important question may eventually become not “What infection do I have?” but “What biological system is preventing recovery?” This is the conclusion I keep returning to.

Imagine ten people exposed to the same organism.

One develops neurological disease. One develops arthritis. One develops vascular symptoms. One develops severe fatigue. One becomes highly reactive. Several recover.

The organism is not the only variable.

The host is different.

One person may have excellent mitochondrial reserve, efficient glutamate clearance, stable endothelial function, strong antioxidant recycling, and an immune system capable of resolving the response.

Another person may begin with weaker mitochondrial reserve, altered immune genetics, endothelial vulnerability, poor redox buffering, abnormal gut function, autonomic instability, or reduced ability to tolerate inflammatory metabolic stress.

Once infection occurs, those differences can determine where the system fails first.

That means the limiting factor can be different in every person. In one patient the dominant problem may still be active microbial replication. In another it may be persistent immune activation. In another it may be endothelial dysfunction. In another it may be mitochondrial respiratory limitation. In another it may be abnormal kynurenine metabolism, glutamate handling, mast-cell signaling, nutrient deficiency, or autonomic dysfunction.

And sometimes the infection may no longer be the main reason the person remains ill.

This is why a positive antibody result cannot explain an entire chronic illness by itself. Exposure, active microbial replication, host injury, and persistent immune dysregulation are different biological states.

The goal should therefore not be to identify ten pathways and immediately try to treat all ten. The goal is to identify which mechanism is actually dominant.

If the phenotype is neurological, I would want to understand the neuroimmune environment, tryptophan-kynurenine pathway, glutamate handling, calcium signaling, and mitochondrial energy metabolism.

If the phenotype is strongly vascular or orthostatic, I would think more carefully about endothelial physiology, microcirculation, autonomic regulation, blood-volume distribution, and small-fiber function.

If profound fatigue and exertional intolerance dominate, I would want to separate inflammatory metabolic reprogramming from actual mitochondrial respiratory limitation, impaired oxygen delivery, autonomic dysfunction, and nutrient deficiencies.

If mineral abnormalities dominate, I would want to know whether they represent true deficiency or inflammatory redistribution.

If oxidative stress is severe, I would want to identify the source instead of simply suppressing the signal.

That is what I mean when I talk about moving from diagnosis toward mechanism.

The model I am increasingly developing is no longer simply infection causes symptoms. It is that pathogen biology interacts with pathogen burden, tissue location, immune response, mitochondrial capacity, endothelial function, redox reserve, genetics, microbiome, nutritional status, previous infections, and environmental exposures. Together those factors determine the phenotype.

The pathogen may initiate the disturbance, but the host determines what that disturbance becomes.

And once enough systems begin interacting, the illness can become self-reinforcing. Inflammation changes metabolism. Altered metabolism changes redox state. Redox stress can impair mitochondria. Poor mitochondrial function can compromise ATP-dependent processes such as glutamate handling. Greater excitatory signaling can increase calcium demand. Calcium can increase mitochondrial metabolic pressure. Endothelial dysfunction can reduce tissue perfusion and oxygen delivery. Poor perfusion adds another energetic burden. Each pathway begins affecting the others.

At that point, chronic illness is no longer one straight line from bacterium to symptom. It has become a network.

That is where my research is going now. I am continuing to investigate Lyme disease and Bartonella through the intersection of pathogen metabolism, immune evasion, PI3K-AKT-mTOR-HIF immunometabolism, glutamate and glutamine cycling, alpha-ketoglutarate and succinate metabolism, tryptophan and kynurenine biology, quinolinic acid, mast-cell calcium signaling, endothelial function, mitochondrial redox biology, heme and mineral metabolism, and individual host susceptibility.

I am also looking more closely at these pathways in the complex cases I work with, not because I want to force every unexplained symptom into an infection model, but because I want enough mechanistic resolution to determine what the infection can explain, what it cannot explain, and which system has actually become the bottleneck preventing recovery.